T
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Price:
70.53
CNY
4.03%
Market Closed
Market Cap:
¥5.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
T
|
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
|
CN |
|
M
|
Multi Hanna Kreasindo Tbk PT
IDX:MHKI
|
ID |
|
C
|
Cubic Sensor and Instrument Co Ltd
SSE:688665
|
CN |
|
Mufin Green Finance Ltd
NSE:MUFIN
|
IN |
|
H
|
Hardwyn India Ltd
NSE:HARDWYN
|
IN |
|
L
|
Lay Hong Bhd
KLSE:LAYHONG
|
MY |
Income Statement
Earnings Waterfall
Tibet Duo Rui Pharmaceutical Co Ltd
Tibet Duo Rui Pharmaceutical Co Ltd
Income Statement
Tibet Duo Rui Pharmaceutical Co Ltd
Tibet Duo Rui Pharmaceutical Co Ltd
Currency: CNY
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
3
|
4
|
4
|
5
|
8
|
11
|
0
|
0
|
|
| Revenue |
490
N/A
|
512
+5%
|
558
+9%
|
555
0%
|
530
-5%
|
481
-9%
|
471
-2%
|
436
-7%
|
401
-8%
|
406
+1%
|
386
-5%
|
345
-11%
|
334
-3%
|
335
+0%
|
314
-6%
|
289
-8%
|
241
-17%
|
212
-12%
|
197
-7%
|
177
-10%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(44)
|
(58)
|
(64)
|
(63)
|
(60)
|
(64)
|
(74)
|
(89)
|
(93)
|
(115)
|
(113)
|
(104)
|
(106)
|
(129)
|
(151)
|
(155)
|
(149)
|
(135)
|
(152)
|
(154)
|
|
| Gross Profit |
446
N/A
|
454
+2%
|
494
+9%
|
493
0%
|
469
-5%
|
417
-11%
|
397
-5%
|
346
-13%
|
308
-11%
|
291
-5%
|
273
-6%
|
241
-12%
|
228
-5%
|
206
-10%
|
163
-21%
|
134
-18%
|
92
-31%
|
77
-17%
|
45
-41%
|
23
-48%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(342)
|
(359)
|
(401)
|
(403)
|
(396)
|
(360)
|
(354)
|
(309)
|
(295)
|
(289)
|
(260)
|
(233)
|
(216)
|
(195)
|
(173)
|
(166)
|
(180)
|
(179)
|
(173)
|
(179)
|
|
| Selling, General & Administrative |
(348)
|
(360)
|
(396)
|
(394)
|
(373)
|
(351)
|
(346)
|
(307)
|
(273)
|
(265)
|
(239)
|
(216)
|
(196)
|
(186)
|
(159)
|
(140)
|
(131)
|
(132)
|
(122)
|
(115)
|
|
| Research & Development |
(23)
|
(26)
|
(28)
|
(24)
|
(23)
|
(24)
|
(24)
|
(20)
|
(22)
|
(29)
|
(30)
|
(28)
|
(22)
|
(20)
|
(18)
|
(27)
|
(35)
|
(40)
|
(50)
|
(60)
|
|
| Depreciation & Amortization |
(9)
|
(0)
|
(0)
|
0
|
(11)
|
0
|
0
|
0
|
(12)
|
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
(15)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
38
|
27
|
23
|
15
|
11
|
15
|
17
|
18
|
11
|
4
|
9
|
11
|
13
|
11
|
4
|
1
|
1
|
(7)
|
(1)
|
(4)
|
|
| Operating Income |
103
N/A
|
95
-8%
|
93
-3%
|
89
-4%
|
73
-18%
|
57
-23%
|
43
-23%
|
38
-13%
|
13
-66%
|
2
-84%
|
13
+558%
|
7
-44%
|
12
+57%
|
11
-10%
|
(10)
N/A
|
(33)
-229%
|
(88)
-172%
|
(102)
-16%
|
(129)
-25%
|
(155)
-21%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(2)
|
(2)
|
(2)
|
(2)
|
0
|
2
|
5
|
8
|
8
|
7
|
7
|
8
|
10
|
10
|
10
|
9
|
4
|
(3)
|
(9)
|
(15)
|
|
| Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
0
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
101
N/A
|
93
-8%
|
91
-3%
|
88
-3%
|
73
-16%
|
59
-20%
|
48
-18%
|
45
-6%
|
21
-54%
|
9
-56%
|
21
+122%
|
16
-22%
|
22
+39%
|
21
-5%
|
1
-97%
|
(24)
N/A
|
(86)
-252%
|
(105)
-23%
|
(138)
-31%
|
(171)
-24%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
(11)
|
(11)
|
(11)
|
(9)
|
(7)
|
(5)
|
(5)
|
(5)
|
(2)
|
(2)
|
(2)
|
(1)
|
(5)
|
(5)
|
(5)
|
(3)
|
1
|
1
|
1
|
(0)
|
|
| Income from Continuing Operations |
90
|
82
|
80
|
78
|
66
|
53
|
43
|
40
|
19
|
8
|
19
|
15
|
17
|
16
|
(4)
|
(27)
|
(85)
|
(104)
|
(137)
|
(171)
|
|
| Income to Minority Interest |
2
|
3
|
3
|
3
|
3
|
2
|
2
|
1
|
2
|
2
|
2
|
3
|
2
|
3
|
5
|
10
|
22
|
28
|
35
|
46
|
|
| Net Income (Common) |
92
N/A
|
85
-7%
|
83
-3%
|
81
-3%
|
69
-15%
|
56
-19%
|
45
-19%
|
42
-8%
|
21
-51%
|
9
-55%
|
21
+129%
|
17
-18%
|
19
+9%
|
19
-1%
|
1
-94%
|
(18)
N/A
|
(63)
-257%
|
(76)
-21%
|
(102)
-35%
|
(125)
-23%
|
|
| EPS (Diluted) |
1.15
N/A
|
1.07
-7%
|
1.03
-4%
|
1.01
-2%
|
1.05
+4%
|
0.69
-34%
|
0.56
-19%
|
0.52
-7%
|
0.26
-50%
|
0.11
-58%
|
0.26
+136%
|
0.22
-15%
|
0.24
+9%
|
0.23
-4%
|
0.02
-91%
|
-0.23
N/A
|
-0.79
-243%
|
-0.94
-19%
|
-1.31
-39%
|
-1.57
-20%
|
|
Switch to:
Switch to:
See Also
Discover More
